Chitosan Membranes Stabilized with Varying Acyl Lengths Release Cis-2-Decenoic Acid and Bupivacaine at Controlled Rates and Inhibit Pathogenic Biofilm

Front Biosci (Landmark Ed). 2024 Mar 18;29(3):108. doi: 10.31083/j.fbl2903108.

Abstract

Background: Adherence of complex bacterial biofilm communities to burned tissue creates a challenge for treatment, with infection causing 51% of burn victim deaths. This study evaluated the release of therapeutics from wound care biomaterials and their antimicrobial activity against pathogens Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Methods: Electrospun chitosan membranes (ESCMs) were fabricated and acylated with chain lengths ranging from 6-10 carbons then loaded with 0.15 mg of anti-biofilm agent, cis-2-decenoic acid (C2DA), and 0.5 mg of local anesthetic, bupivacaine.

Results: Combinations of therapeutics released from modified ESCMs at a cumulative amount of 45-70% of bupivacaine and less than 20% of C2DA. Results from bacterial studies suggest that this combination reduced biofilm 10-fold for S. aureus, 2-fold for Acinetobacter baumannii, and 2-3-fold for Pseudomonas aeruginosa by 24 hours. Additionally, dual loaded groups reduced planktonic Staphylococcus aureus ~4-fold by 24 hours as well as Acinetobacter baumannii ~3-fold by 48 hours.

Conclusions: The combination of therapeutics used has a significant role in biofilm prevention for selected strains via direct contact or diffusion in aqueous solutions.

Keywords: C2DA; anhydride; biofilm; biomaterial; bupivacaine; chitosan; drug delivery; electrospinning; infection.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Biofilms
  • Bupivacaine / pharmacology
  • Chitosan* / pharmacology
  • Fatty Acids, Monounsaturated*
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections*
  • Staphylococcal Infections*
  • Staphylococcus aureus

Substances

  • 2-decenoic acid
  • Chitosan
  • Bupivacaine
  • Anti-Bacterial Agents
  • Fatty Acids, Monounsaturated